Chongqing Zhifei Bio Products (300122) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chongqing Zhifei Bio Products (300122) has a cash flow conversion efficiency ratio of 0.048x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.42 Billion ≈ $207.88 Million USD) by net assets (CN¥29.61 Billion ≈ $4.33 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chongqing Zhifei Bio Products - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Chongqing Zhifei Bio Products's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Chongqing Zhifei Bio Products carry for a breakdown of total debt and financial obligations.
Chongqing Zhifei Bio Products Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Zhifei Bio Products ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rigetti Computing Inc
NASDAQ:RGTI
|
-0.037x |
|
Grupo Catalana Occidente
MC:GCO
|
0.098x |
|
Plexus Corp
NASDAQ:PLXS
|
-0.010x |
|
Kumba Iron Ore Ltd
JSE:KIO
|
0.169x |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
0.095x |
|
LYFT Inc
NASDAQ:LYFT
|
0.085x |
|
Thai Airways International Public Company Limited
BK:THAI
|
0.005x |
|
Black Hills Corporation
NYSE:BKH
|
0.043x |
Annual Cash Flow Conversion Efficiency for Chongqing Zhifei Bio Products (2007–2024)
The table below shows the annual cash flow conversion efficiency of Chongqing Zhifei Bio Products from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 300122 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥30.83 Billion ≈ $4.51 Billion |
CN¥-4.41 Billion ≈ $-645.91 Million |
-0.143x | -150.14% |
| 2023-12-31 | CN¥31.51 Billion ≈ $4.61 Billion |
CN¥9.00 Billion ≈ $1.32 Billion |
0.286x | +247.93% |
| 2022-12-31 | CN¥24.24 Billion ≈ $3.55 Billion |
CN¥1.99 Billion ≈ $291.06 Million |
0.082x | -82.97% |
| 2021-12-31 | CN¥17.66 Billion ≈ $2.58 Billion |
CN¥8.51 Billion ≈ $1.24 Billion |
0.482x | +13.66% |
| 2020-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
CN¥3.50 Billion ≈ $511.68 Million |
0.424x | +78.23% |
| 2019-12-31 | CN¥5.75 Billion ≈ $841.02 Million |
CN¥1.37 Billion ≈ $200.03 Million |
0.238x | +69.81% |
| 2018-12-31 | CN¥4.18 Billion ≈ $611.80 Million |
CN¥585.59 Million ≈ $85.69 Million |
0.140x | +102.07% |
| 2017-12-31 | CN¥2.94 Billion ≈ $429.85 Million |
CN¥203.61 Million ≈ $29.79 Million |
0.069x | +94.27% |
| 2016-12-31 | CN¥2.52 Billion ≈ $368.94 Million |
CN¥89.95 Million ≈ $13.16 Million |
0.036x | -60.57% |
| 2015-12-31 | CN¥2.47 Billion ≈ $361.33 Million |
CN¥223.45 Million ≈ $32.70 Million |
0.090x | +37.81% |
| 2014-12-31 | CN¥2.46 Billion ≈ $359.64 Million |
CN¥161.39 Million ≈ $23.62 Million |
0.066x | -29.19% |
| 2013-12-31 | CN¥2.39 Billion ≈ $349.62 Million |
CN¥221.58 Million ≈ $32.42 Million |
0.093x | +94.94% |
| 2012-12-31 | CN¥2.37 Billion ≈ $347.24 Million |
CN¥112.89 Million ≈ $16.52 Million |
0.048x | -51.45% |
| 2011-12-31 | CN¥2.26 Billion ≈ $330.43 Million |
CN¥221.25 Million ≈ $32.38 Million |
0.098x | +287.24% |
| 2010-12-31 | CN¥2.14 Billion ≈ $313.40 Million |
CN¥54.19 Million ≈ $7.93 Million |
0.025x | -94.57% |
| 2009-12-31 | CN¥451.69 Million ≈ $66.10 Million |
CN¥210.61 Million ≈ $30.82 Million |
0.466x | -12.05% |
| 2008-12-31 | CN¥267.06 Million ≈ $39.08 Million |
CN¥141.58 Million ≈ $20.72 Million |
0.530x | -10.72% |
| 2007-12-31 | CN¥188.03 Million ≈ $27.52 Million |
CN¥111.66 Million ≈ $16.34 Million |
0.594x | -- |
About Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal P… Read more